JOURNAL PRESENTATION. Dr Tina Fan Tseung Kwan O Hospital 17 th Jan 2013
|
|
- Jared Kelly
- 5 years ago
- Views:
Transcription
1 JOURNAL PRESENTATION Dr Tina Fan Tseung Kwan O Hospital 17 th Jan 2013
2 THE COMBINATION OF OCTREOTIDE AND MIDODRINE IS NOT SUPERIOR TO ALBUMIN IN PREVENTING RECURRENCE OF ASCITES AFTER LARGE-VOLUME PARACENTESIS CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2012 OCT Khurram Bari et al
3
4 Refractory ascites Ascites that has failed to respond to standard treatment of dietary salt restriction and diuretics: spironolactone 400 mg and furosemide 160 mg/day), or appearance of diuretic-induced complications International Ascites Club definition
5 Current Mx of refractory ascites
6 Current Mx of refractory ascites First-line recommended therapy: large-volume paracentesis (LVP) + IV albumin (recommended by AASLD and EASL) IV albumin can prevent the development of postparacentesis circulatory dysfunction (PCD) PCD is defined as a significant increase (50%) in plasma renin activity (PRA) 6 days after LVP PCD is associated with faster recurrence of ascites, development of hepatorenal syndrome, dilutional hyponatremia and reduced survival
7 Postparacentesis circulatory dysfunction
8 Summary of studies exploring plasma volume expansion and development of PCD
9 Use of vasoconstrictors Vasoconstrictors
10 Terlipressin Use in HRS Meta-analysis of all randomized, controlled trials assessing the effects of terlipressin on renal function Forest plot of random effects meta-analysis of randomized trials on vasconstrictors alone or with albumin Vs no intervention or albumin for HRS. The outcome measure is all-cause mortality Hepatology 2010;51:576 84
11 Midodrine hydrochloride an α1-agonist, orally available Increases effective circulating blood volume and renal perfusion by increasing systemic and splanchnic blood pressure Midodrine is a prodrug that is absorbed from the gastrointestinal tract and metabolized by the liver into an active metabolite, desglymidodrine, eliminated in urine Approved by the US Food and Drug Administration to treat symptomatic orthostatic hypotension. Investigations of midodrine alone or in combination have shown conflicting results for systemic and renal hemodynamics and renal function in patients with cirrhosis-related complications
12 Octreotide Octreotide is known to inhibit the secretion of glucagon (a vasodilator that may play a role in cirrhosis-associated vasodilation) In patients with HRS, octreotide administration alone does not elicit any vasoconstrictor/vasopressor effect and does not improve renal function Midodrine plus octreotide, which has the advantage of subcutaneous administration, appears to have some efficacy. However, there are no randomized clinical trials and the study numbers are small
13 5-10mg tds for 3days 12.5 mg tds for 2days LAR 20mg IM
14 THE COMBINATION OF OCTREOTIDE AND MIDODRINE IS NOT SUPERIOR TO ALBUMIN IN PREVENTING RECURRENCE OF ASCITES AFTER LARGE-VOLUME PARACENTESIS CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2012 OCT Khurram Bari et al
15 Aims of the study compare the effect of long-term administration of the combination of vasoconstrictors, octreotide/midodrine Vs standard single-dose albumin after LVP in the recurrence of ascites and the development of PCD in patients with cirrhosis and refractory ascites
16 Study design prospective, randomized, double-blind, double-placebo, controlled trial comparing intravenous albumin Vs vasoconstrictors (combination of octreotide long acting release and midodrine) after LVP in patients with cirrhosis and refractory ascites.
17 Study patients Inclusion criteria: Age between 18 and 80 years old cirrhosis of any etiology diagnosed by liver biopsy or based on firm clinical grounds, refractory ascites Exclusion criteria: hepatic hydrothorax Small amount of ascites recent (within 1 mo) gastrointestinal hemorrhage active bacterial infection cardiac failure findings suggestive of organic renal disease hepatocellular carcinoma baseline serum creatinine level greater than 3.0 mg/dl
18
19 Low salt diet and held diuretics for minimal 3 days Index LVP Body weight, abdominal girth, heart rate, BP, routine blood test, blood test for aldosterone and PRA Control group IV albumin 8g/L of ascitic fluid removed + IM 5m of saline solution (octreotide placebo) every mon. + one tablet (midodrine placebo) tds Study group IV infusion of saline solution (albumin placebo) + IM 20mg octreotide every month (long acting) + one tablet 10 mg of midodrine tds Follow-up visits at days 6 and 15, and then monthly after randomization detailed history and physical examination: any alcohol use, weight, abdominal girth, mean arterial pressure (MAP), routine laboratory tests, spot urine sodium and creatinine, and blood samples for aldosterone and PRA
20 Primary end point Time to recurrence of ascites Defined as the requirement of a repeat LVP, as indicated by the presence of moderate to severe ascites and weight gain to 90% to 100% of baseline weight and an increase in abdominal girth to 90% to 100% of baseline abdominal girth
21 Secondary end points 1. The development of PCD, defined as an increase in PRA by more than 50% from baseline to a level greater than 4 ng/ml/h at postparacentesis day 6 2. Average changes in mean arterial pressure and heart rate from baseline as surrogates of the hyperdynamic circulatory state 3. Development of hepatorenal syndrome (HRS) defined as the development of de novo HRS or progression from type 2 to type 1 HRS Criteria for diagnosis of hepatorenal syndrome were based on recommendations of the International Ascites Club
22 The study was to be terminated and the study medications discontinued: Development of primary end point (ie, recurrence of ascites requiring LVP) death liver transplant or completion of 6 months of study drugs from randomization
23 Statistical Analysis Time to recurrence of ascites was calculated and event-free survival was estimated in each group using the Kaplan Meier method with 95% confidence intervals. Analysis for secondary outcomes included changes in plasma renin activity, pulse, MAP at day 6 from baseline, and development of HRS type I at the time of repeat paracentesis An independent sample t test was used to compare means of variables with normal distribution and a nonparametric test (Mann Whitney U test) was used to compare medians of variables with non-normal distribution Additional analysis included changes in model for end-stage liver disease (MELD) score, serum creatinine level, and serum sodium level at the time of repeat paracentesis Results were considered significant for a P value less than.05 and a confidence interval of 95% IBM SPSS version 19.0 (Armonk, NY) was used
24 RESULTS
25
26 Primary and secondary outcomes
27
28 Effect on renal function and MELD score
29 Change of renin activity
30 Long term follow up evaluation 25 patients 9 patients died 9 patients alive and required freq paracentesis 4 patients received liver transplant 2 patients were lost 1 patient in albumin gp has not required repeat paracentesis Albumin gp : 4 Vasoconstrictor gp: 5 Albumin gp: 5 Vasoconstrictor gp : 4 Albumin gp: 2 Vasoconstrictor gp: 2 Albumin gp: 1 Vasoconstrictor gp :1
31 Conclusion of the study Double-blind, placebo-controlled, proof-of concept study, long-term administration of a combination of orally administered midodrine and intramuscular long-acting octreotide was not superior to albumin in delaying the recurrence of ascites after LVP or in preventing PCD
32 Limitations of the study small sample size fixed dose of midodrine/ octreotide, not titrated to increases in mean arterial pressure did not evaluate the adherence to midodrine
33 Vasoconstrictor use in ascites patient? Probably not the combination of midodrine and octerotide Use more potent vasoconstrictor like terlipressin Different combinations of vasoconstrictors Right dosage and duration of vasoconstrictors
34 Albumin infusion seems to be better! Time to recurrence of ascites: 10 days (albumin gp) Vs 8 days ( vasoconstrictor gp) P=0.318 Rate of PCD: 18% ( albumin gp) Vs 25% ( vasoconstrictor gp) P=0.574 At the time of recurrent ascites, serum Creat is higher in vasoconstrictor gp: 1.2mg/dL ( vasoconstrictor gp) Vs 0.9mg/dL (albumin gp) P=0.051 MELD score decreased in Albumin gp ( 2 )and slightly increased in vasoconstrictor gp ( 0.5 ) P=0.033 Albumin gp is sicker at baseline ( higher Child score)
35
36
37
38 Current Mx of refractory ascites
39 END Thank you!
Management of Cirrhotic Complications Uncontrolled Ascites. Siwaporn Chainuvati, MD Siriraj Hospital Mahidol University
Management of Cirrhotic Complications Uncontrolled Ascites Siwaporn Chainuvati, MD Siriraj Hospital Mahidol University Topic Definition, pathogenesis Current therapeutic options Experimental treatments
More informationInitial approach to ascites
Ascites: Filling and Draining the Water Balloon Common Pathogenesis in Refractory Ascites, Hyponatremia, and Cirrhosis intrahepatic resistance sinusoidal portal hypertension Splanchnic vasodilation (effective
More informationNorepinephrine versus Terlipressin for the Treatment of Hepatorenal Syndrome
Norepinephrine versus Terlipressin for the Treatment of Hepatorenal Syndrome Disclosure I have no conflicts of interest to disclose Name: Margarita Taburyanskaya Title: PharmD, PGY1 Pharmacy Practice Resident
More informationManagement of Acute Decompensation of Cirrhosis JOHN O GRADY KING S COLLEGE HOSPITAL
Management of Acute Decompensation of Cirrhosis JOHN O GRADY KING S COLLEGE HOSPITAL Terminology Acute decompensation of cirrhosis - stable patient with sudden deterioration Acute-on-chronic liver failure
More informationHepatorenal syndrome. Jan T. Kielstein Departent of Nephrology Medical School Hannover
Hepatorenal syndrome Jan T. Kielstein Departent of Nephrology Medical School Hannover Hepatorenal Syndrome 1) History of HRS 2) Pathophysiology of HRS 3) Definition of HRS 4) Clinical presentation of HRS
More informationAscites is the most frequent complication of cirrhosis,
Beneficial Effect of Midodrine in Hypotensive Cirrhotic Patients with Refractory Ascites G & H C l i n i c a l C a s e S t u d i e s Achuthan Sourianarayanane, MD, MRCP 1 David S. Barnes, MD 1,2 Arthur
More informationThe Management of Ascites & Hepatorenal Syndrome. Florence Wong University of Toronto. Falk Symposium March 14, 2008
The Management of Ascites & Hepatorenal Syndrome Florence Wong University of Toronto Falk Symposium March 14, 2008 Management of Ascites Sodium Restriction Mandatory at all stages of ascites in order to
More informationManagement of Ascites and Hepatorenal Syndrome. Florence Wong University of Toronto. June 4, /16/ Gore & Associates: Consultancy
Management of Ascites and Hepatorenal Syndrome Florence Wong University of Toronto June 4, 2016 6/16/2016 1 Disclosures Gore & Associates: Consultancy Sequana Medical: Research Funding Mallinckrodt Pharmaceutical:
More informationAscites Management. Atif Zaman, MD MPH Oregon Health & Science University Professor of Medicine Division of Gastroenterology and Hepatology
Ascites Management Atif Zaman, MD MPH Oregon Health & Science University Professor of Medicine Division of Gastroenterology and Hepatology Disclosure 1. The speaker Atif Zaman, MD MPH have no relevant
More informationFrom Sodium Retention to Therapy for Refractory Ascites The Role for New Drugs. Florence Wong University of Toronto. Falk Symposium October 14, 2007
From Sodium Retention to Therapy for Refractory Ascites The Role for New Drugs Florence Wong University of Toronto Falk Symposium October 14, 2007 Sodium Retention in Cirrhosis Occurs as a result of hemodynamic
More informationBeta-blockers in cirrhosis: Cons
Beta-blockers in cirrhosis: Cons Eric Trépo MD, PhD Dept. of Gastroenterology. Hepatopancreatology and Digestive Oncology. C.U.B. Hôpital Erasme. Université Libre de Bruxelles. Bruxelles. Belgium Laboratory
More informationEDUCATION PRACTICE. Management of Refractory Ascites. Clinical Scenario. The Problem
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2005;3:1187 1191 EDUCATION PRACTICE Management of Refractory Ascites ANDRÉS CÁRDENAS and PERE GINÈS Liver Unit, Institute of Digestive Diseases, Hospital Clínic,
More informationHepatorenal syndrome. Jan Jan T. T. Kielstein Departent of of Nephrology Medical School School Hannover
Hepatorenal syndrome Jan Jan T. T. Kielstein Departent of of Nephrology Medical School School Hannover Hepatorenal Syndrome 1) History of HRS 2) Pathophysiology of HRS 3) Definition of HRS 4) Clinical
More informationFilippo Schepis, MD Università degli Studi di Modena e Reggio Emilia
Filippo Schepis, MD Università degli Studi di Modena e Reggio Emilia Il sottoscritto dichiara di non aver avuto/di aver avuto negli ultimi 12 mesi conflitto d interesse in relazione a questa presentazione
More informationREVIEW. Ariel W. Aday, M.D.,* Nicole E. Rich, M.D.,* Arjmand R. Mufti, M.D., and Shannan R. Tujios, M.D.
REVIEW CON ( The Window Is Closed ): In Patients With Cirrhosis With Ascites, the Clinical Risks of Nonselective beta-blocker Outweigh the Benefits and Should NOT Be Prescribed Ariel W. Aday, M.D.,* Nicole
More informationDeveloped for Scotland by the National Plasma Product Expert Advisory Group. Clinical Guidelines for Human Albumin Use
Approved by NPPEAG 10 December 2010 Reviewed 1 June 2012 To be reviewed 1 June 2014 Developed for Scotland by the National Plasma Product Expert Advisory Group Clinical Guidelines for Human Albumin Use
More informationManagement of refractory ascites in cirrhosis: Are we out of date?
Submit a Manuscript: http://www.wjgnet.com/esps/ Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx DOI: 10.4254/wjh.v8.i28.1182 World J Hepatol 2016 October 8; 8(28): 1182-1193 ISSN 1948-5182 (online)
More informationProf. Mohammad Umar. MBBS, MCPS, FCPS, FACG (USA), FRCP (London), FRCP (Glasgow), FAGA
Prof. Mohammad Umar MBBS, MCPS, FCPS, FACG (USA), FRCP (London), FRCP (Glasgow), FAGA Chairman and Head Department of Medicine Rawalpindi Medical College, Rawalpindi. Consultant Gastroenterologist / Hepatologist
More informationEDUCATION PRACTICE. Cirrhosis With Refractory Ascites: Serial Large Volume Paracentesis, TIPS, or Transplantation?
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2011;9:931 935 EDUCATION PRACTICE Cirrhosis With Refractory Ascites: Serial Large Volume Paracentesis, TIPS, or Transplantation? VANDANA KHUNGAR* and SAMMY SAAB*,
More informationAdrenal Insufficiency in Patients with Liver Cirrhosis and Severe Sepsis: Effect on Survival after Treatment with Hydrocortisone ABSTRACT
20 Original Article Adrenal Insufficiency in Patients with Liver Cirrhosis and Severe Sepsis: Effect on Survival after Treatment with Hydrocortisone Pattanasirigool C Prasongsuksan C Settasin S Letrochawalit
More informationHepatorenal Syndrome
Necker Seminars in Nephrology Institut Pasteur Paris, April 22, 2013 Hepatorenal Syndrome Dr. Richard Moreau 1 INSERM U773, Centre de Recherche Biomédicale Bichat-Beaujon CRB3, 2 Université Paris Diderot
More informationBETA-BLOCKERS IN CIRRHOSIS.PRO.
BETA-BLOCKERS IN CIRRHOSIS.PRO. Angela Puente Sánchez. MD PhD Hepatology Unit. Gastroenterology department Marques de Valdecilla University Hospital. Santander INTRODUCTION. Natural history of cirrhosis
More informationManagement of the Cirrhotic Patient in the ICU
Management of the Cirrhotic Patient in the ICU Peter E. Morris, MD Professor & Chief, Pulmonary, Critical Care and Sleep Medicine University of Kentucky Conflict of Interest Funding US National Institutes
More informationDeveloped for Scotland by the National Plasma Product Expert Advisory Group. Clinical Guidelines for Human Albumin Use
Approved by NPPEAG 28 May 2018 Reviewed 1 June 2018 To be reviewed 1 June 2020 Developed for Scotland by the National Plasma Product Expert Advisory Group Clinical Guidelines for Human Albumin Use 1 National
More informationEASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis
EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis European Association for the Study of the Liver 1 Ascites is the
More informationPortal hypertension is the main complication of cirrhosis
GASTROENTEROLOGY 2001;120:726 748 Current Management of the Complications of Cirrhosis and Portal Hypertension: Variceal Hemorrhage, Ascites, and Spontaneous Bacterial Peritonitis GUADALUPE GARCIA TSAO
More informationThe Yellow Patient. Dr Chiradeep Raychaudhuri, Consultant Hepatologist, Hull University Teaching Hospitals NHS Trust
The Yellow Patient Dr Chiradeep Raychaudhuri, Consultant Hepatologist, Hull University Teaching Hospitals NHS Trust there s a yellow patient in bed 40. It s one of yours. Liver Cirrhosis Why.When.What.etc.
More informationEnd-Stage Liver Disease (ESLD): A Guide for HIV Physicians
Slide 1 of 32 End-Stage Liver Disease (ESLD): A Guide for HIV Physicians Marion G. Peters, MD John V. Carbone, MD, Endowed Chair Professor of Medicine Chief of Hepatology Research University of California
More informationCIRCULATORY AND RENAL FAILURE IN CIRRHOSIS
CIRCULATORY AND RENAL FAILURE IN CIRRHOSIS Pere Ginès, MD Liver Unit, Hospital Clínic Barcelona, Catalunya, Spain CIRCULATORY AND RENAL FAILURE IN CIRRHOSIS Hecker R and Sherlock S, The Lancet 1956 RENAL
More informationTherapy Insight: management of hepatorenal syndrome
Therapy Insight: management of hepatorenal syndrome Andrés Cárdenas and Pere Ginès* SUMMARY Hepatorenal syndrome (HRS), a feared complication of advanced cirrhosis, is characterized by functional renal
More informationESLD a Guide for HIV Physicians. Marion Peters University of California San Francisco June 2015
ESLD a Guide for HIV Physicians Marion Peters University of California San Francisco June 2015 Disclosures Honararia from Johnson and Johnson Roche Merck Gilead Spouse employee of Hoffman La Roche Natural
More informationL USO DELLA RISORSA ALBUMINA LA PROSPETTIVA DEL CLINICO
AISF-SIMTI POSITION PAPER - L USO APPROPRIATO DELL ALBUMINA Roma, 29 marzo 2016 L USO DELLA RISORSA ALBUMINA LA PROSPETTIVA DEL CLINICO Mauro Bernardi Semeiotica Medica Dipartimento di Scienze Mediche
More informationAscites and hepatorenal syndrome in cirrhosis: pathophysiological basis of therapy and current management
Journal of Hepatology 38 (2003) S69 S89 www.elsevier.com/locate/jhep Ascites and hepatorenal syndrome in cirrhosis: pathophysiological basis of therapy and current management Vicente Arroyo*, Jordi Colmenero
More informationChronic Hepatic Disease
Chronic Hepatic Disease 10 th Leading Cause of Death Liver Functions Energy Metabolism Protein Synthesis Solubilization, Transport, and Storage Protects and Clears drugs, damaged cells Causes of Liver
More informationManagement of Cirrhosis Related Complications
Management of Cirrhosis Related Complications Ke-Qin Hu, MD, FAASLD Professor of Clinical Medicine Director of Hepatology University of California, Irvine Disclosure I have no disclosure related to this
More informationControversies in Management of Portal Hypertension and Cirrhosis Complications in the Transplant Candidate
Controversies in Management of Portal Hypertension and Cirrhosis Complications in the Transplant Candidate Patrick Northup, MD, FAASLD, FACG Medical Director, Liver Transplantation University of Virginia
More informationConflict of interest disclosures. Complications of end stage liver disease. None. The many complications of Cirrhosis. Portal Hypertension.
Complications of end stage liver disease Conflict of interest disclosures None Amir Qamar, MD Instructor of Medicine Brigham and Women s s Hospital Harvard Medical School Boston, MA 02115 The many complications
More informationHepatorenal syndrome a defined entity with a standard treatment?
Hepatorenal syndrome a defined entity with a standard treatment? Falk Symposium 162 Dresden - October 14, 2007 Alexander L. Gerbes Klinikum of the University of Munich Grosshadern Department of Medicine
More informationPORTAL HYPERTENSION An Introduction to the Culprit of Many Liver Failure Complications
PORTAL HYPERTENSION An Introduction to the Culprit of Many Liver Failure Complications Edy G. Trujillo, RN, MSN, ACNP-BC Liver Transplant RRUCLA Medical Center July 31, 2018 What Do We All Look Forward
More informationOriginal Article. Noradrenaline is as Effective as Terlipressin in Hepatorenal Syndrome Type 1: A Prospective, Randomized Trial
30 Journal of The Association of Physicians of India Vol. 64 September 2016 Original Article Noradrenaline is as Effective as Terlipressin in Hepatorenal Syndrome Type 1: A Prospective, Randomized Trial
More informationINCIDENCE OF BACTERIAL INFECTIONS IN CIRRHOSIS
INCIDENCE OF BACTERIAL INFECTIONS IN CIRRHOSIS Yoshida H et al (1993)* Deschenes M et al (1999)** Strauss E et al (1993) Borzio M et al (2002) PATIENTS 1140 140 170 405 INFECTIONS 15.4% 20% 47% 34% * Many
More informationManaging Cirrhosis. Cirrhosis of the liver is a progressive, fibrosing. Ascites. By Cameron Ghent, MD, FRCPC. Complications of Cirrhosis
Focus on CME at the University of Western Ontario Managing Cirrhosis By Cameron Ghent, MD, FRCPC Cirrhosis of the liver is a progressive, fibrosing process resulting in nodule formation and microvascular
More informationPLASMA COPEPTIN AS A BIOMARKER OF DISEASE PROGRESSION AND PROGNOSIS IN CIRRHOSIS. Journal of Hepatology 2016;65:
PLASMA COPEPTIN AS A BIOMARKER OF DISEASE PROGRESSION AND PROGNOSIS IN CIRRHOSIS Journal of Hepatology 2016;65:914-920 ABSTRACT Background: Research on vasopressin (AVP) in cirrhosis and its role in the
More informationTreating patients with end-stage liver disease: Are we ready? Dr. Mino R. Mitri, M.D., C.M., M.Ed., FRCPC
Treating patients with end-stage liver disease: Are we ready? Dr. Mino R. Mitri, M.D., C.M., M.Ed., FRCPC mino.mitri@ubc.ca No Conflict of Interest 157 patients 157 patients 6 transplanted Criteria Liver
More informationSign up to receive ATOTW weekly -
HEPATORENAL SYNDROME ANAESTHESIA TUTORIAL OF THE WEEK 240 10 TH SEPTEMBER 2011 Gerry Lynch Rotherham General Hospital Correspondence to gerry.lynch@rothgen.nhs.uk QUESTIONS Before continuing, try to answer
More informationSteps in Assessing Fibrosis 4/30/2015. Overview of Liver Disease Associated With HCV
Overview of Liver Disease Associated With HCV Marion G. Peters, MD John V. Carbone, Endowed Chair Professor of Medicine Chief of Hepatology Research University of California San Francisco San Francisco,
More informationCIRRHOTIC MANAGEMENT
DISCLAIMER: These guidelines were prepared by the Department of Surgical Education, Orlando Regional Medical Center. They are intended to serve as a general statement regarding appropriate patient care
More informationPHARMACEUTICAL INFORMATION AZILSARTAN
AZEARLY Tablets Each Tablet Contains Azilsartan 20/40/80 mg PHARMACEUTICAL INFORMATION AZILSARTAN Generic name: Azilsartan Chemical name: 2-Ethoxy-1-{[2'-(5-oxo-2,5-dihydro-1,2,4-oxadiazol-3-yl)-4-biphenylyl]methyl}-
More informationRISK STRATIFICATION IN CIRRHOSIS: FOCUS ON UMBILICAL HERNIA Sam Hawkins MD PGY5
RISK STRATIFICATION IN CIRRHOSIS: FOCUS ON UMBILICAL HERNIA Sam Hawkins MD PGY5 PATIENT PRESENTATION 73M w/ Hep B Cirrhosis, HTN, DM II Liver disease followed at OSH x2 years (when moved from China), on
More informationPioneering Innovative Therapies for Liver Disease
Pioneering Innovative Therapies for Liver Disease Investor Presentation January 2017 Forward-Looking Statements This document contains forward-looking statements made pursuant to the safe harbor provisions
More informationCOMPLICATIONS OF CIRRHOSIS: ASCITES & HEPATIC ENCEPHALOPATHY
COMPLICATIONS OF CIRRHOSIS: ASCITES & HEPATIC ENCEPHALOPATHY DR. ESTER YAGUDAYEVA CLINICAL PHARMACIST HOSPICE PHARMACY SOLUTIONS OBJECTIVES Understand the prognosis of End Stage Liver Disease (ESLD) Identify
More informationElevated Creatinine in a Patient With Cirrhosis
REVIEW Elevated Creatinine in a Patient With Cirrhosis Heather L. Klavan, M.D., and Brett E. Fortune, M.D., M.S. Elevation in serum creatinine is a common laboratory finding for patients with cirrhosis
More informationThe Continuum of Care for Advanced Liver Disease: Partnering with the Liver Specialist. K V Speeg, MD, PhD UT Health San Antonio
The Continuum of Care for Advanced Liver Disease: Partnering with the Liver Specialist K V Speeg, MD, PhD UT Health San Antonio Objectives Review staging of liver disease Review consequences of end-stage
More informationCIRRHOSIS Definition
Cirrhosis Update Robert S. Brown, Jr., MD, MPH Vice Chair, Transitions of Care Interim Chief, Division of Gastroenterology & Hepatology Weill Cornell Medical College CIRRHOSIS Definition Irreversible fibrous
More informationOptimal management of ascites
Optimal management of ascites P. Angeli, Dept. of Medicine, Unit of Internal Medicine and epatology (), University of Padova (Italy) pangeli@unipd.it 10th Paris epatology Conference National Conference
More informationPathophysiology, diagnosis and treatment of ascites in cirrhosis
Annals of hepatology 2002; 1(2): April-June: 72-79 Concise Review Annals of hepatology Pathophysiology, diagnosis and treatment of ascites in cirrhosis Vicente Arroyo 1, M.D. Abstract The mechanism by
More informationWe are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors
We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 4,100 116,000 120M Open access books available International authors and editors Downloads Our
More informationThis survey aims to look at individual practice and can be completed by any healthcare professional.
This survey aims to look at individual practice and can be completed by any healthcare professional. If you have any questions about how this form should be completed please contact Dr Grace Ting (ghlting@doctors.net.uk)
More informationCase Report Low-Dose Tolvaptan for the Treatment of Dilutional Hyponatremia in Cirrhosis: A Case Report and Literature Review
Case Reports in Hepatology, Article ID 795261, 4 pages http://dx.doi.org/10.1155/2014/795261 Case Report Low-Dose Tolvaptan for the Treatment of Dilutional Hyponatremia in Cirrhosis: A Case Report and
More informationThe Use of Albumin for the Prevention of Hepatorenal Syndrome in Patients with Spontaneous Bacterial Peritonitis and Cirrhosis
The Use of Albumin for the Prevention of Hepatorenal Syndrome in Patients with Spontaneous Bacterial Peritonitis and Cirrhosis http://www.funnyjunk.com/funny_pictures/1743659/enlarged/ Daniel Giddings,
More informationVasoconstrictor Therapy in Hepatorenal Syndrome: When to Use it and How
KidneyCon Little Rock, AR, April 7 th, 2018 Vasoconstrictor Therapy in Hepatorenal Syndrome: When to Use it and How Juan Carlos Q. Velez, MD Associate Professor of Medicine, Ochsner Clinical School / The
More informationFollow this and additional works at: Part of the Medicine and Health Sciences Commons
Virginia Commonwealth University VCU Scholars Compass Internal Medicine Publications Dept. of Internal Medicine 2017 Reversal of hepatorenal syndrome type 1 with terlipressin plus albumin vs. placebo plus
More informationTerlipressin: An Asset for Hepatologists!
DIAGNOSTIC AND THERAPEUTIC ADVANCES IN HEPATOLOGY Terlipressin: An Asset for Hepatologists! S.K. Sarin and Praveen Sharma One Case Scenario A 48-year-old male with alcoholic cirrhosis who was abstinent
More informationEsophageal Varices Beta-Blockers or Band Ligation. Cesar Yaghi MD Hotel-Dieu de France University Hospital Universite Saint Joseph
Esophageal Varices Beta-Blockers or Band Ligation Cesar Yaghi MD Hotel-Dieu de France University Hospital Universite Saint Joseph Esophageal Varices Beta-Blockers or Band Ligation? Risk of esophageal variceal
More informationT herapeutic (that is, total) paracentesis is used in patients
90 LIVER AND BILIARY DISEASE Comparison of the effect of terlipressin and albumin on arterial blood volume in patients with cirrhosis and tense ascites treated by : a randomised pilot study R Moreau, T
More informationISPUB.COM. Management of Ascites. V Mahesh SOURCE OF SUPPORT DIAGNOSIS OF ASCITES INTRODUCTION CAUSES [,] DIAGNOSTIC TESTS
ISPUB.COM The Internet Journal of Gastroenterology Volume 5 Number 2 Management of Ascites V Mahesh Citation V Mahesh. Management of Ascites. The Internet Journal of Gastroenterology. 2006 Volume 5 Number
More informationManagement of Hospitalized Patients with Cirrhosis
Disclosure Management of Hospitalized Patients with Cirrhosis Research Support: Gilead, Genfit, Conatus and Intercept Advisory: Gilead Bilal Hameed, MD Associate Professor of Medicine Division of Transplant
More informationCOMPOSITION. A film coated tablet contains. Active ingredient: irbesartan 75 mg, 150 mg or 300 mg. Rotazar (Film coated tablets) Irbesartan
Rotazar (Film coated tablets) Irbesartan Rotazar 75 mg, 150 mg, 300 mg COMPOSITION A film coated tablet contains Active ingredient: irbesartan 75 mg, 150 mg or 300 mg. Rotazar 75 mg, 150 mg, 300 mg PHARMACOLOGICAL
More informationHepatology on the AMU
Hepatology on the AMU RCP day, 8 th February 2018 Jo Leithead Consultant in Hepatology and Liver Transplantation Addenbrookes Hospital Cambridge Is liver disease relevant to me? Williams R, Lancet 2014
More informationMANAGING END STAGE LIVER DISEASE IN RESOURCE LIMITED SETTINGS
MANAGING END STAGE LIVER DISEASE IN RESOURCE LIMITED SETTINGS Mark W. Sonderup Division of Hepatology and Liver Laboratory Department of Medicine University of Cape Town & Groote Schuur Hospital Cirrhosis..
More information0BCore Safety Profile. Pharmaceutical form(s)/strength: Film-coated tablet 40, 80, 160, 320 mg SE/H/PSUR/0024/003 Date of FAR:
0BCore Safety Profile Active substance: Valsartan Pharmaceutical form(s)/strength: Film-coated tablet 40, 80, 160, 320 mg P-RMS: SE/H/PSUR/0024/003 Date of FAR: 28.02.2013 4.2 Posology and method of administration
More informationHepatorenal syndrome
Annals of Hepatology 2003; 2(1): January-March: 23-29 Concise Review Annals of Hepatology Hepatorenal syndrome Andrés Cárdenas, M.D., 1 Vicente Arroyo, M.D. 2 Abstract Hepatorenal syndrome is complication
More informationThe Kidney in Liver Disease. Jeff Kaufhold MD FACP Nephrology Assoc. of Dayton Oct 2018
The Kidney in Liver Disease Jeff Kaufhold MD FACP Nephrology Assoc. of Dayton Oct 2018 Objectives 1. Understand new evidence in the pathophysiology of Hepatorenal syndrome 2. Review current treatment guidelines
More informationHepatorenal Syndrome in Cirrhosis: Pathogenesis and Treatment
GASTROENTEROLOGY 2002;122:1658-1676 Hepatorenal Syndrome in Cirrhosis: Pathogenesis and Treatment VICENTE ARROYO, MONICA GUEVARA, and PERE GINI~S Liver Unit, Institute of Digestive Disease, Hospital Clinic,
More informationSystemic Inflammatory Response Syndrome and MELD Score in Hospital Outcome of Patients with Liver Cirrhosis
168 Original Article Systemic Inflammatory Response Syndrome and MELD Score in Hospital Outcome of Patients with Liver Cirrhosis Ramin Behroozian 1*, Mehrdad Bayazidchi 1, Javad Rasooli 1 1. Department
More informationAlcoholic Hepatitis: Management Options
Alcoholic Hepatitis: Management Options Paul J. Thuluvath, MD. FRCP Institute of Digestive Health & Liver Diseases, Mercy Medical Center, Baltimore Professor of Surgery & Medicine, Georgetown University,
More informationACUTE-ON-CHRONIC LIVER FAILURE: DEFINITION, DIAGNOSIS AND CLINICAL CHARACTERISTICS.
ACUTE-ON-CHRONIC LIVER FAILURE: DEFINITION, DIAGNOSIS AND CLINICAL CHARACTERISTICS. Vicente Arroyo 1, 2, Rajiv Jalan 2, 3 1 Institut de Investigacions Biomèdiques August Pi I Sunyer. University of Barcelona.
More informationHepatitis C: How sick can we treat? Robert S. Brown, Jr., MD, MPH Vice Chair, Transitions of Care Interim Chief, Division of
Hepatitis C: How sick can we treat? Robert S. Brown, Jr., MD, MPH Vice Chair, Transitions of Care Interim Chief, Division of Gastroenterology & Hepatology www.livermd.org HCV in advanced disease In principle
More informationDIAGNOSIS AND MANAGEMENT OF DIURETIC RESISTANCE. Jules B. Puschett, M.D.
DIAGNOSIS AND MANAGEMENT OF DIURETIC RESISTANCE Jules B. Puschett, M.D. Diuretic Resistance A clinical circumstance in which patients do not respond to a combination of salt restriction and even large
More informationACG & AASLD Joint Clinical Guideline: Prevention and Management of Gastroesophageal Varices and Variceal Hemorrhage in Cirrhosis
ACG & AASLD Joint Clinical Guideline: Prevention and Management of Gastroesophageal Varices and Variceal Hemorrhage in Cirrhosis Guadalupe Garcia-Tsao, M.D., 1 Arun J. Sanyal, M.D., 2 Norman D. Grace,
More informationfollowing the last documented transfusion; thereafter, evaluate the residual impairment(s).
Adult Listings 5.01 Category of Impairments, Digestive System 5.02 Gastrointestinal hemorrhaging from any cause, requiring blood transfusion (with or without hospitalization) of at least 2 units of blood
More informationEvaluating HIV Patient for Liver Transplantation. Marion G. Peters, MD Professor of Medicine University of California San Francisco USA
Evaluating HIV Patient for Liver Transplantation Marion G. Peters, MD Professor of Medicine University of California San Francisco USA Slide 2 ESLD and HIV Liver disease has become a major cause of death
More informationAscites is the most common complication of cirrhosis and. Natural History of Patients Hospitalized for Management of Cirrhotic Ascites
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2006;4:1385 1394 Natural History of Patients Hospitalized for Management of Cirrhotic Ascites RAMON PLANAS,* SILVIA MONTOLIU,* BELEN BALLESTÉ, MONICA RIVERA, MIREIA
More informationContraindications. Indications. Complications. Currently TIPS is considered second or third line therapy for:
Contraindications Absolute Relative Primary prevention variceal bleeding HCC if centrally located Active congestive heart failure Obstruction all hepatic veins Thomas D. Boyer, M.D. University of Arizona
More informationCirrhosis Complications
Cirrhosis Complications and Spontaneous Bacterial Peritonitis While these complications greatly increase mortality from decompensated cirrhosis, effective treatment is possible with early diagnosis. Vigilant
More informationCare of the Patient With Cirrhosis
REVIEW Care of the Patient With Cirrhosis Anitha Yadav, M.D., and Hugo E. Vargas, M.D. Caring for patients with cirrhosis involves multidisciplinary and timely management of several complications while
More informationHepatorenal Syndrome
Review Abdussalam Shredi MD, Sakolwan Suchartlikitwong MD, Hawa Edriss MD Abstract Hepatorenal syndrome is a form of acute kidney injury that occurs in chronic liver disease and acute fulminant liver failure.
More informationTreatment and management of ascites and hepatorenal syndrome: an update
564673TAG0010.1177/1756283X14564673Therapeutic Advances in GastroenterologyK. Lenz et al. review-article2014 Therapeutic Advances in Gastroenterology Review Treatment and management of ascites and hepatorenal
More informationContempo GIMSI Cosa cambia alla luce della letteratura in tema di terapia farmacologica
Contempo GIMSI 2015-2017 Cosa cambia alla luce della letteratura in tema di terapia farmacologica Dott.ssa Diana Solari Centro Aritmologico e Sincope Unit, Lavagna www.gimsi.it POST 2 (Prevention of Syncope
More informationManagement of Acute Heart Failure
Management of Acute Heart Failure Uri Elkayam, MD Professor of Medicine University of Southern California School of Medicine Los Angeles, California elkayam@usc.edu ADHF Treatments Goals.2 Improve symptoms.
More informationHepatocellular Carcinoma. Markus Heim Basel
Hepatocellular Carcinoma Markus Heim Basel Outline 1. Epidemiology 2. Surveillance 3. (Diagnosis) 4. Staging 5. Treatment Epidemiology of HCC Worldwide, liver cancer is the sixth most common cancer (749
More informationApproved regimens for cirrhotic patients
5th Workshop on HCV THERAPY ADVANCES New antivirals in clinical practice Approved regimens for cirrhotic patients Amsterdam, 4-5 december 2015 Disease burden in Spain 400000 350000 300000 F0 Peak cirrhosis
More informationHepatorenal Syndrome and AKI in Cirrhosis
Hepatorenal Syndrome and AKI in Cirrhosis Luis S. Marsano, MD Professor of Medicine Division of Gastroenterology, Hepatology and Nutrition University of Louisville and Louisville VAMC 2015 HRS Hepatorenal
More informationHEPATOrenal Syndrome Type I: Correct Diagnosis = Correct Management
HEPATOrenal Syndrome Type I: Correct Diagnosis = Correct Management Stephen G. M. Wong BSc, BSc(Med), MD, MHSc, FRCPC Associate Professor of Medicine Director, Hepatology Education Section of Hepatology
More informationHepatorenal Syndrome 2018
Hepatorenal Syndrome 2018 Warren Kupin, MD FACP Professor of Medicine Miami Transplant Institute Katz Family Division of Nephrology and Hypertension University of Miami Miller School of Medicine creat
More informationAscites. Rationale. Scope. Definition of Terms. Standard of Care
Ascites Rationale This guideline is adapted for inter-professional primary care providers working in various settings in Fraser Health, British Columbia and the Fraser Valley Cancer Center and any other
More informationForward-looking Statements
Forward-looking Statements This presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding
More informationRENAL DISEASE IN END STAGE LIVER DISEASE
RENAL DISEASE IN END STAGE LIVER DISEASE Mitchell L Shiffman, MD Director Health System Richmond and Newport News, VA Medical Group Good Help to Those in Need Mitchell L Shiffman, MD POTENTIAL CONFLICTS
More informationAntihypertensive Agents Part-2. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia
Antihypertensive Agents Part-2 Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia Agents that block production or action of angiotensin Angiotensin-converting
More information